NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-31 18:05இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Gem Aromatics Q2FY27 Cons. Revenue Up 16.2% to Rs 104 Cr; PAT Loss at Rs 7.0 Cr Post Dahej Capex
Gem Aromatics reported a 16.2% YoY rise in consolidated revenue to Rs 104.0 Cr for Q2FY27, alongside gross margin expansion to 25.4% from 14.0% in Q2FY26. However, consolidated net loss stood at Rs 7.0 Cr (vs net loss of Rs 2.58 Cr in Q2FY26), heavily impacted by Rs 9.5 Cr in quarterly depreciation following the capitalization of ~Rs 265 Cr Dahej capex. For H1FY27, consolidated revenue grew 14.5% YoY to Rs 202.8 Cr with a net loss of Rs 14.9 Cr. Commercial shipments of new cooling agents have commenced, while Safranal and MEHQ production starts will contribute to revenue in Q3 and Q4 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the Q2 and H1FY27 investor presentation following the capitalization of ~Rs 265 Cr capex at the Dahej multi-purpose facility.
ஏன் இது முக்கியம்The company is transitioning from capital expenditure to commercial ramp-up for specialty aroma molecules and MEHQ, but profitability remains depressed under heavy fixed depreciation and debt charges.
📅 குறுகிய காலம்The headline net loss driven by fixed depreciation and working capital drag could keep stock sentiment cautious until higher Dahej utilization materializes.
📈 நீண்ட காலம்Structural transformation hinges on successfully commercializing higher-margin Phenol derivatives (MEHQ) and cooling agents to achieve company-targeted FY28 revenue of Rs 1,050-1,100 Cr.
⚠ அபாய எச்சரிக்கைகள்
Significant rise in short-term debt to Rs 219.0 Cr driven by working capital lock-up in inventory (Rs 321.7 Cr).
High fixed depreciation burden (Rs 9.5 Cr/quarter) suppressing net profits until utilization reaches optimal levels.
👀 கவனிக்க வேண்டியவை
Track the capacity utilization ramp-up at Dahej and margin trends in Q3FY27 to verify if operating leverage starts offsetting the Rs 9.5 Cr quarterly depreciation charge.
Gem Aromatics Q2 Standalone PAT Rises 116% YoY to Rs 8.90 Cr; Revenue Dips 6.1%
Gem Aromatics reported standalone revenue from operations of Rs 92.38 Cr for Q2 FY27 (quarter ended Sep 30, 2026), down 6.1% YoY from Rs 98.40 Cr, but up 11.3% QoQ from Rs 82.99 Cr. Standalone net profit rose sharply by 116.6% YoY to Rs 8.90 Cr compared to Rs 4.11 Cr in Q2 FY26, driven by lower raw material consumption costs. For H1 FY27, standalone revenue stood flat at Rs 175.37 Cr versus Rs 174.80 Cr YoY, while PAT jumped 52% to Rs 16.16 Cr. The company also shifted its inventory valuation policy from Weighted Average Cost to FIFO prospectively from April 1, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுGem Aromatics announced its Q2 and H1 FY27 results alongside a prospective change in its inventory valuation method to FIFO.
ஏன் இது முக்கியம்Demonstrates a strong recovery in standalone net profitability despite top-line headwinds from raw material volatility and US tariff pressures.
📅 குறுகிய காலம்The sharp YoY expansion in quarterly net profit and sequential revenue growth is likely to support near-term market sentiment after a prolonged stock drawdown.
📈 நீண்ட காலம்Crucial to monitor full consolidated profitability and product mix transition towards higher-margin Phenol derivatives (MEHQ) away from commoditized Mint products.
⚠ அபாய எச்சரிக்கைகள்
Prospective-only change to FIFO inventory valuation makes past period margins not strictly comparable
Exposure to US tariffs and export demand volatility
👀 கவனிக்க வேண்டியவை
Track subsequent quarters to observe if operating margin improvements sustain, especially considering the prospective inventory accounting change to FIFO, and monitor the ramp-up of the Dahej facility.
Q1 FY27 Concall: Cons Revenue ₹99 Cr, Net Loss ₹7.9 Cr as ₹265 Cr Dahej Capex Capitalized
Gem Aromatics reported Q1 FY27 consolidated revenue of ₹99 Cr (up 12.5% YoY from ₹88 Cr), but posted a consolidated net loss of ₹7.9 Cr due to ₹9.1 Cr of depreciation following the capitalization of its Dahej facility. The company has incurred ~₹265 Cr out of its planned ~₹270 Cr capex (representing ~75% of TTM revenue). EBITDA margin stood at 3.3% on a consolidated basis, impacted by operating drag at the new plant and raw material disruptions in the clove vertical caused by Madagascar floods. Management expects commercial supplies from new verticals (cooling agents, Safranal, and phenol derivatives) to scale meaningfully from Q3 and Q4 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுManagement provided detailed product qualification and revenue ramp-up timelines for new specialty molecules at the Dahej facility following recent asset capitalization.
ஏன் இது முக்கியம்The company is transitioning from a mint-dependent business to high-value aroma chemicals and phenol derivatives; near-term earnings remain under pressure from fixed depreciation until new capacity ramps up.
📅 குறுகிய காலம்Profitability is expected to stay subdued in Q2 FY27 due to fixed operating costs and depreciation, with initial volume traction expected in Q3 FY27.
📈 நீண்ட காலம்Successful commercialization of non-mint specialty aroma chemicals and phenol derivatives could expand operating margins towards management's medium-term targets as operating leverage kicks in.
⚠ அபாய எச்சரிக்கைகள்
Raw material supply disruptions and price volatility (e.g., Madagascar clove supply)
Near-term return ratios pressured by high capitalized asset base
👀 கவனிக்க வேண்டியவை
Track the quarterly commercialization progress and capacity utilization of the Dahej facility over Q2–Q4 FY27, along with gross margin recovery in the clove vertical.
Rs 265 Cr Dahej Capex Capitalized; Q1FY27 Revenue Up 13% but PAT Turns Negative
Gem Aromatics reported a 13% YoY increase in consolidated revenue to Rs 98.9 Cr for Q1FY27, but posted a net loss of Rs 7.9 Cr compared to a profit of Rs 8.0 Cr in the previous year. The bottom line was severely impacted by a 405% surge in depreciation (Rs 9.1 Cr) following the capitalization of the Rs 265 Cr Dahej facility. Gross margins contracted significantly to 16.7% from 29.5% due to higher raw material costs and a seasonally softer product mix. The company is transitioning its portfolio toward higher-value specialty molecules, with commercial production of phenol derivatives expected in Q3FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a heavy capex phase to an operational phase at its Dahej plant, leading to high non-cash depreciation charges that are currently masking operating performance.
ஏன் இது முக்கியம்The Rs 265 Cr investment is massive relative to the company's FY26 revenue of Rs 366.5 Cr; the company's future profitability depends on successfully scaling high-margin specialty products to offset these new fixed costs.
📅 குறுகிய காலம்The stock may face pressure due to the reported net loss and significant margin contraction, as the market digests the impact of high depreciation on the bottom line.
📈 நீண்ட காலம்Structural significance is high if the company successfully ramps up the Dahej facility and achieves its target of 16-18% EBITDA margins by shifting away from the volatile mint segment.
⚠ அபாய எச்சரிக்கைகள்
High depreciation impacting net profitability
Raw material price volatility (Clove and Mint)
Execution risk in ramping up new specialty chemical lines
👀 கவனிக்க வேண்டியவை
Monitor the utilization ramp-up at the Dahej facility and the margin trajectory as the product mix shifts toward specialty chemicals; watch for the start of revenue from cooling agents and phenol derivatives in H2FY27.
Gem Aromatics Q1 FY27: Revenue Up 12.8% YoY to ‡98.9 Cr; PAT Turns to ‡7.9 Cr Loss
Gem Aromatics reported a 12.8% YoY increase in consolidated revenue to ‡98.9 cr for Q1 FY27, but faced a sharp decline in profitability. The company posted a consolidated net loss of ‡7.9 cr, down from a profit of ‡8.0 cr in Q1 FY26, primarily due to a 1,282 bps contraction in gross margins. This margin pressure was driven by higher raw material costs (clove floods in Madagascar) and a ‡9.1 cr depreciation charge following the capitalization of the ‡265 cr Dahej facility. Management expects revenue from new high-margin verticals like Phenol derivatives to begin contributing meaningfully from Q4 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a profitable entity to a loss-making one at the consolidated level as it begins to absorb the high depreciation and operating costs of its massive ‡265 cr expansion.
ஏன் இது முக்கியம்The ‡265 cr capex is significant relative to the company's FY26 revenue of ‡256 cr; the current loss highlights the 'gestation pain' where fixed costs are capitalized before the new capacity generates matching revenue.
📅 குறுகிய காலம்The stock may face pressure due to the unexpected consolidated loss and sharp margin erosion, despite the modest YoY revenue growth.
📈 நீண்ட காலம்The structural shift toward higher-margin Phenol and Aroma chemicals is critical for the company to reach its ‡1,050-1,100 cr revenue target by FY28; however, near-term profitability remains at risk from high fixed costs.
⚠ அபாய எச்சரிக்கைகள்
High fixed-cost burden (depreciation) impacting net profit
Raw material price volatility in the Clove and Mint segments
Execution risk in ramping up the new Dahej facility
👀 கவனிக்க வேண்டியவை
Watch for the utilization levels of the Dahej facility over the next two quarters; the key trigger will be the commencement of commercial Phenol derivative production in Q3/Q4 FY27 to offset high fixed costs.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Gem Aromatics Q1 Standalone PAT Up 11% to ₹7.25 Cr; Consolidated Swings to ₹7.87 Cr Loss
Gem Aromatics reported a mixed Q1 FY27 performance with standalone revenue growing 8.6% YoY to ₹82.99 cr and standalone PAT rising 11.2% to ₹7.25 cr. However, the consolidated results show a significant net loss of ₹7.87 cr, compared to a profit of ₹7.98 cr in the same quarter last year, indicating a heavy drag from subsidiaries. The company also transitioned its inventory valuation method from Weighted Average to FIFO effective April 1, 2026, which was applied prospectively due to the complexity of its manufacturing processes.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 financial results and implemented a significant change in accounting policy for inventory valuation (Weighted Average to FIFO).
ஏன் இது முக்கியம்The sharp divergence between standalone and consolidated performance highlights the current financial burden of the company's expansion phase, specifically the new Dahej multi-purpose facility.
Standalone Revenue (Q1 FY27): ₹82.99 கோடிConsolidated Net Loss (Q1 FY27): ₹7.87 கோடிStandalone PAT Growth (YoY): 11.2%Consolidated EPS: ₹(1.56)Standalone Finance Costs: ₹1.33 கோடி
📅 குறுகிய காலம்The stock may face pressure due to the substantial consolidated loss and the lack of restated comparative figures following the accounting policy change.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to shift its product mix toward higher-margin Phenol derivatives and achieve its FY28 revenue target of ₹1,050-1,100 cr.
⚠ அபாய எச்சரிக்கைகள்
Significant consolidated net loss
Accounting policy change (FIFO) prevents direct historical inventory comparison
High drag from subsidiary operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the operational ramp-up and path to profitability for the Dahej facility (Krystal Ingredients), which appears to be the primary driver of the consolidated losses.
Gem Aromatics to Expand into Brazil with ₹17 Cr Investment; Appoints New Auditors
Gem Aromatics Limited has approved the incorporation of a wholly-owned subsidiary in Brazil to distribute essential oils and specialty chemicals. The company plans to invest up to ₹2 crore in equity and provide a Standby Letter of Credit (SBLC) of up to ₹15 crore for this international venture. Additionally, the board has appointed M/s. N. L. Bhatia & Associates as Secretarial Auditors for a five-year term and re-appointed M/s. RANK & Associates as Internal Auditors. This expansion signals a strategic push into the South American market to support its global distribution network.
முக்கிய அம்சங்கள்
Approved the incorporation of a Wholly Owned Subsidiary in Brazil for the distribution of essential and specialty chemicals.Total financial commitment for the Brazil entity includes ₹2 crore equity investment and ₹15 crore SBLC.M/s. N. L. Bhatia & Associates appointed as Secretarial Auditors for a 5-year term from FY 2026-27 to FY 2030-31.M/s. RANK & Associates re-appointed as Internal Auditors for the Financial Year 2026-27.The new Brazil entity will also handle distribution for the company's material subsidiary, Krystal Ingredients Private Limited.
👀 கவனிக்க வேண்டியவை
Investors should view the Brazil expansion as a positive growth indicator for the company's export business. Monitor future updates regarding the subsidiary's operational commencement and its contribution to the consolidated top line.
Yash Parekh, the Managing Director and CEO of Gem Aromatics Limited, has acquired 1,43,760 equity shares through an open market transaction on June 02, 2026. The total value of the acquisition is approximately ₹2.18 crore. This purchase has increased his personal stake in the company from 9.11% to 9.38%. Significant insider buying by a top executive is typically interpreted as a strong signal of confidence in the company's future performance and valuation.
முக்கிய அம்சங்கள்
MD & CEO Yash Parekh purchased 1,43,760 shares from the open marketTotal transaction value stands at approximately ₹2.18 croreIndividual stake increased from 9.11% (47,59,397 shares) to 9.38% (49,03,157 shares)The transaction was executed on June 02, 2026, and reported on June 04, 2026
👀 கவனிக்க வேண்டியவை
This insider buying suggests that the leadership believes the stock is undervalued or expects positive developments. Investors should consider this a positive factor in their fundamental analysis of the company.
Gem Aromatics Q4 FY26: Consolidated Revenue up 40% QoQ, Targets ₹1,100 Cr Revenue by FY28
Gem Aromatics reported a strong sequential recovery in Q4 FY26, with consolidated revenue growing 40% QoQ to ₹110 crore and EBITDA surging 124% to ₹16 crore. The company turned a consolidated profit of ₹1 crore, recovering from a ₹5 crore loss in Q3, despite high depreciation costs. A major milestone was the commencement of production at the Dahej greenfield facility, which has a peak revenue potential of ₹800 crore. Management has provided a long-term guidance of ₹1,100 crore in consolidated turnover with 16-18% EBITDA margins by FY28.
முக்கிய அம்சங்கள்
Consolidated revenue grew 40% QoQ to ₹110 crore with EBITDA margins improving to 14.2%.Completed ₹260 crore of the planned ₹270 crore capex for the Dahej facility, which is now operational.The Dahej plant is expected to deliver an asset turn of 3-3.5x, representing ₹800 crore in peak revenue potential.Management targets consolidated revenue of ₹1,100 crore and EBITDA margins of 16-18% by FY28.Silvassa plant received the EcoVadis Platinum sustainability rating, placing it in the top tier globally.
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization ramp-up at the new Dahej facility and the stabilization of phenol prices, which are currently impacting production timelines. The long-term revenue target of ₹1,100 crore offers a significant growth trajectory worth watching.
Gem Aromatics Q4FY26: Sequential Recovery with PAT at ₹1 Cr; FY26 Revenue at ₹366.5 Cr
Gem Aromatics reported a consolidated revenue of ₹366.5 Cr for FY26, a decline from ₹504.0 Cr in FY25. While Q4FY26 showed a sequential recovery with revenue rising to ₹110.4 Cr from ₹78.9 Cr in Q3, the consolidated PAT for the full year dropped sharply to ₹1.4 Cr from ₹53.4 Cr. Profitability was significantly impacted by higher depreciation charges following the capitalization of the ₹260 Cr Dahej facility and volatility in petrochemical raw material prices.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 stood at ₹366.5 Cr, down from ₹504.0 Cr in the previous fiscal year.Q4FY26 Consolidated PAT turned positive at ₹1.0 Cr compared to a loss of ₹5.0 Cr in Q3FY26.Capitalized approximately ₹260 Cr of the planned ₹270 Cr capex for the Dahej facility, leading to increased depreciation costs.Commenced commercial production of GEM Cool 5 and Safranal at the Dahej facility on February 26, 2026.The Silvassa plant received the EcoVadis Platinum sustainability rating, placing it in the top global tier for ESG.
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization levels of the newly capitalized Dahej facility and the stabilization of phenol prices, as the company's current bottom line is suppressed by high depreciation and raw material volatility.
Gem Aromatics Q4FY26: Revenue up 40% QoQ to ₹110 Cr; PAT Returns to Black at ₹1 Cr
Gem Aromatics reported a sequential recovery in Q4FY26 with consolidated revenue growing 40% QoQ to ₹110.4 Cr, although YoY performance remains down by 45.4%. The company returned to profitability with a PAT of ₹1 Cr compared to a ₹5 Cr loss in the previous quarter, despite being weighed down by ₹9 Cr in depreciation following the ₹260 Cr Dahej plant capitalization. EBITDA margins improved to 14.2% from 8.9% QoQ, driven by better price realization and a healthier product mix. However, high raw material costs for phenol continue to impact the derivatives segment production timelines.
முக்கிய அம்சங்கள்
Consolidated Q4 revenue grew 39.9% QoQ to ₹110.4 Cr, though it fell 45.4% YoY compared to FY25.EBITDA margins expanded to 14.2% in Q4 from 8.9% in Q3, aided by operating leverage and better realizations.Capitalized ₹260 Cr Dahej capex, leading to a significant increase in quarterly depreciation to ₹9 Cr.Commenced commercial production of GEM Cool 5 and Safranal at the Dahej facility in February 2026.Phenol derivatives business remains production-ready but impacted by high raw material price volatility.
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization ramp-up at the Dahej facility, as high depreciation will continue to pressure net margins in the short term. The sequential recovery is encouraging, but sustained volume growth is needed to offset the increased fixed cost base from recent expansions.
Gem Aromatics Approves FY26 Results, Appoints New Directors and Cost Auditor
Gem Aromatics Limited held its board meeting on May 21, 2026, to approve the audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company received a clean audit report with an unmodified opinion from its statutory auditors, Chhajed & Doshi. Significant leadership changes were announced, including the appointment of a new Whole Time Director and an Independent Director. Furthermore, the board approved the appointment of M/s Y.R. Doshi & Associates as the Cost Auditor for the financial year 2026-27.
முக்கிய அம்சங்கள்
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.Statutory auditors issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies.Appointed Mr. Dinesh Vasu Thekkepanakkal as an Additional (Whole Time) Director.Appointed Mr. Nandan Narula as an Additional (Independent) Director to the Board.Appointed M/s Y.R. Doshi & Associates as the Cost Auditor for the upcoming FY 2026-27.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial performance in the full audit report to evaluate the company's profitability trends. The clean audit opinion and board expansion are positive indicators of corporate governance.
Promoter Yash Parekh Increases Stake in Gem Aromatics by 0.19% via Open Market Purchase
Mr. Yash Parekh, a member of the promoter group of Gem Aromatics Limited, has increased his stake in the company by acquiring 100,000 equity shares. The transaction was executed through the open market on March 25, 2026, representing a 0.19% stake. This acquisition raises his total holding from 8.92% to 9.11% of the company's total voting capital. Such insider buying is generally perceived as a positive signal regarding the management's confidence in the company's future performance.
முக்கிய அம்சங்கள்
Promoter Yash Parekh acquired 100,000 equity shares (0.19% stake) on March 25, 2026.The acquisition was conducted via open market transactions.Total promoter holding for the individual increased from 46,59,397 shares (8.92%) to 47,59,397 shares (9.11%).The company's total equity base remains at 5,22,37,138 shares with a face value of Rs. 2 each.
👀 கவனிக்க வேண்டியவை
Investors should take note of this promoter buying as it indicates internal confidence in the company's valuation. It is advisable to monitor if this trend of stake increase continues across the promoter group.
Yash Parekh, the Managing Director and CEO of Gem Aromatics Limited, has purchased 100,000 equity shares of the company through an open market transaction on March 25, 2026. The total value of the acquisition is approximately ₹1.56 crore. This purchase increases his personal stake from 8.92% to 9.11%. Insider buying by top management is typically viewed as a strong signal of confidence in the company's future growth and valuation.
முக்கிய அம்சங்கள்
MD & CEO Yash Parekh purchased 1,00,000 equity shares via the open market on NSE.The total transaction value is ₹1,56,50,000 (approximately ₹1.56 crore).The promoter's individual shareholding increased from 46,59,397 (8.92%) to 47,59,397 (9.11%).The transaction was completed and disclosed to the exchange on March 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this insider buying as a positive indicator of management's commitment and confidence in the company's prospects. It may be worth monitoring for further accumulation by the promoter group.
Yash Parekh, the Managing Director and CEO of Gem Aromatics Limited, has increased his stake in the company through an open market purchase on March 24, 2026. He acquired 1,25,000 equity shares, representing approximately 0.24% of the company, for a total consideration of ₹1.97 crore. This acquisition raises his total shareholding from 8.68% to 8.92%. Insider buying at the MD/CEO level is typically viewed as a strong signal of management's confidence in the company's future performance and intrinsic value.
முக்கிய அம்சங்கள்
MD & CEO Yash Parekh purchased 1,25,000 equity shares via an on-market transaction on the NSE.The total transaction value amounted to ₹1,97,12,500, excluding taxes and brokerage.Individual shareholding of the promoter increased from 45,34,397 shares (8.68%) to 46,59,397 shares (8.92%).The disclosure was made under SEBI (Prohibition of Insider Trading) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive sign of management's commitment and confidence in the business. It may be worth monitoring the stock for further consolidation or growth following this insider accumulation.
Mrs. Kaksha Vipul Parekh, a member of the promoter group of Gem Aromatics Limited, has acquired 60,000 equity shares through the open market on March 20, 2026. This acquisition represents 0.11% of the company's total paid-up capital. Following this transaction, the promoter group's holding in the company has increased from 9.27% to 9.38%. Such open market purchases by promoters are generally viewed as a sign of confidence in the company's future prospects and valuation.
முக்கிய அம்சங்கள்
Acquisition of 60,000 equity shares (0.11% stake) via open market transactions.Promoter group holding increased from 48,43,219 shares (9.27%) to 49,03,219 shares (9.38%).The total equity capital of the company consists of 5,22,37,138 shares with a face value of Rs. 2 each.The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
👀 கவனிக்க வேண்டியவை
Investors should take note of this insider buying as a positive signal of promoter confidence. While the stake increase is relatively small, it suggests the promoter perceives the current stock price as attractive.
Kaksha Vipul Parekh, the Whole-Time Director and CFO of Gem Aromatics Limited, has purchased 75,000 equity shares of the company through an open market transaction on March 19, 2026. The total acquisition value stands at approximately ₹1.28 crore, excluding taxes and brokerage. This purchase increases the promoter's individual stake from 6.13% to 6.23%. Such insider buying is generally viewed as a positive signal, reflecting management's confidence in the company's future performance and valuation.
முக்கிய அம்சங்கள்
Acquisition of 75,000 equity shares by CFO Kaksha Vipul Parekh via open market on NSETotal transaction value amounts to ₹1,28,23,500 at an implied price of approx ₹171 per shareIndividual shareholding increased from 47,68,219 (6.13%) to 48,43,219 (6.23%)The transaction was disclosed under SEBI (Prohibition of Insider Trading) Regulations
👀 கவனிக்க வேண்டியவை
Investors should take this insider buying as a bullish indicator of management's commitment. It is advisable to monitor if other promoters also increase their stakes in the coming quarters.
Kaksha Vipul Parekh, the Whole-Time Director and CFO of Gem Aromatics Limited, has purchased 60,000 equity shares of the company through an open market transaction on March 17, 2026. This acquisition, valued at approximately Rs 1.03 crore, increases the promoter's stake from 8.87% to 8.98%. Insider buying at market prices is generally interpreted as a strong signal of management's confidence in the company's future performance and current valuation. The transaction was executed on the National Stock Exchange (NSE).
முக்கிய அம்சங்கள்
Promoter and CFO Kaksha Vipul Parekh purchased 60,000 shares on March 17, 2026Total transaction value is approximately Rs 1.03 crore excluding taxes and brokerageIndividual shareholding increased from 46,33,219 shares (8.87%) to 46,93,219 shares (8.98%)The acquisition was conducted via an on-market transaction on the NSE
👀 கவனிக்க வேண்டியவை
Investors should view this insider purchase as a positive indicator of management's conviction in the company's intrinsic value. It may serve as a supportive factor for the stock price in the short to medium term.
Kaksha Vipul Parekh, a Promoter and the Whole-Time Director & CFO of Gem Aromatics, has increased their stake in the company through open market transactions. On March 13, 2026, the promoter purchased a total of 60,000 equity shares across the BSE and NSE platforms. This acquisition, valued at approximately ₹1.05 crore, raised the promoter's individual holding from 8.66% to 8.77%. Insider buying of this nature is generally interpreted as a sign of management's confidence in the company's intrinsic value and future growth.
முக்கிய அம்சங்கள்
Promoter Kaksha Vipul Parekh purchased 60,000 equity shares on March 13, 2026.The total transaction value was approximately ₹1.05 crore excluding taxes and brokerage.The promoter's individual shareholding increased from 8.66% (4,523,219 shares) to 8.77% (4,583,219 shares).The acquisition was conducted through open market purchases on both the BSE and NSE.
👀 கவனிக்க வேண்டியவை
Investors should take note of this insider buying as a positive signal regarding the company's outlook. While the stake increase is relatively small (0.11%), the CFO's personal investment suggests alignment with shareholder interests.
Kaksha Vipul Parekh, the Promoter and CFO of Gem Aromatics Limited, purchased 50,000 equity shares through an open market transaction on March 11, 2026. The acquisition, valued at approximately ₹93.12 lakhs, raised the promoter's stake from 64.54% to 65.27%. This move reflects strong internal confidence in the company's current valuation and long-term business outlook. Insider buying at this scale is often interpreted by the market as a bullish indicator.
முக்கிய அம்சங்கள்
Acquisition of 50,000 equity shares by Promoter and CFO Kaksha Vipul Parekh.Total transaction value reported at ₹93,12,500 through an on-market purchase.Individual promoter holding increased from 64.54% to 65.27% post-transaction.The transaction was executed on March 11, 2026, and disclosed under SEBI PIT regulations.
👀 கவனிக்க வேண்டியவை
Investors should view this insider purchase as a positive signal regarding the company's intrinsic value. It may be worth monitoring the stock for further accumulation by other members of the promoter group.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
